Skip to navigation Skip to content

Cardiomyopathy (CM) Program in Pharmaceutical Benefits Scheme (PBS) 012-24041204

Expand/Collapse all sectionsExpand all


CM restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS CM restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial authority application (PB360)

Symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial grandfather authority application (PB361)

Transthyretin amyloid cardiomyopathy - tafamidis - initial authority application (PB358)

Services Australia website

Cardiomyopathy

External websites

PBS schedule for:

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

If a grandfather patient has not had at least 6 months on optimal dose of mavacamten, will their prescriber need to apply under the first continuing or the second continuing after the grandfather approval?

Prescribers must apply under the first continuing for dose adjustment. If the patient has had at least 6 months on optimal dose, prescribers must apply under the subsequent continuing restriction after the grandfather approval.